$INMB News

INmune Bio Receives R&D Rebates of Approximately $4.6 Million

INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th

INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform

INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform

INmune Bio Reaches Manufacturing Milestone with First Commercial-Ready CORDStrom Umbilical Cord Tissue Processed At CGT Catapult In Partnership With Anthony Nolan Cord Blood Bank

INmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study

INmune Announces Publication Of Peer-Reviewed Study In The Journal Of Neurotrauma On Traumatic Brain Injury And Alzheimer’s; Treatment With Its Lead Neuroinflammation Candidate XPro1595 Prevented Injury-Induced Rise In Amyloid Pathology

INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC

INmune Bio To Present New Imaging Data From Phase 2 Study Of XPro In Patients With Early Alzheimer’s Disease At AAIC

INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion

INmune Bio Submits Its CORDStrom Platform Patent Application Into The U.S. National Phase Before USPTO

INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™

The UK Medicines & Healthcare Products Regulatory Agency Approves The Pediatric Investigation Plan For INmune Bio's Ebstrocel For Recessive Dystrophic Epidermolysis Bullosa

INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB

INmune Bio Receives Official Accepted Meeting Minutes From Recent Pre-MAA Scientific Advice Meeting With UK's MHRA For CORDStrom

INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial

INmune Bio Announces Results From Exploratory Chi-Separation MRI Imaging Analyses From MINDFuL Phase 2 Clinical Trial Of XPro In Patients With Early Alzheimer's Disease

INmune Bio (INMB) Q4 2025 Earnings Transcript

INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform

INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease